Global pharmaceutical company Cipla Limited has received final FDA approval for its Abbreviated New Drug Application for Difluprednate Ophthalmic Emulsion 0.05%. It is AB-rated generic therapeutic equivalent version of Novartis Pharmaceuticals Corporation's Durezol. The company said the product will be available for shipping soon.
Cipla's Difluprednate Ophthalmic Emulsion 0.05% is used for: treatment of inflammation and pain associated with ocular surgery; and treatment of endogenous anterior uveitis.
Cipla is focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.